Current Challenges of R/R MM Management and Innovation Updates

 

Current Challenges of R/R MM Management and Innovation Updates
07:05

ASH 2022 Conference Coverage

ASH 2022 Phase 1/2 Results From MonumenTAL-1: Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in R/R MM

FEATURING Ajai Chari
  • 197 views
  • August 14, 2023
  • 2
25:36

MyCancerHaven

Experts Discuss the Bispecific Antibody Talquetamab in Patients With R/R MM

FEATURING Ravi Vij, Gurbakhash Kaur
  • 227 views
  • July 10, 2023
  • 1
17:42

Abdullah Khan

Treatment Approach in Patients With R/R MM Who Have Failed at Least 4 Lines of Therapies

  • 99 views
  • April 3, 2023
  • 2
41:23

Cleveland Clinic Taussig Cancer Institute

Understanding Resistance in R/R MM: Mechanisms, Current Practice, and Strategies for Overcoming Resistance to Treatment

FEATURING Faiz Anwer
  • 164 views
  • March 22, 2023
  • 3
20:11

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Combination Therapy Trials in Myeloma - A Discussion of Key Oral Abstracts"

FEATURING Andrzej Jakubowiak
  • 305 views
  • June 27, 2023
  • 1
03:33

ecancer

ASCO® 2023 Insights: "TRIMM-2 Study Summary - Update on Talquetamab + Daratumumab for R/R MM"

FEATURING Bhagirathbhai Dholaria
  • 63 views
  • June 14, 2023
05:20

ecancer

ASCO® 2023 Insights: "RedirecTT-1 Study Summary - Teclistamab + Talquetamab Targeting BCMA and GPRC5D in Patients With R/R MM"

FEATURING Yael C. Cohen
  • 78 views
  • June 14, 2023
52:39

Yale Cancer Center

Myeloma in 2023: So Many Drugs, Yet So Few Cures

FEATURING Ajai Chari
  • 517 views
  • May 9, 2023
  • 3
09:10

University of Colorado Division of Hematology

2023 Denver ASH Review: Updates in Multiple Myeloma (Updates in the Use of Bispecific Antibodies)

FEATURING Daniel Sherbenou
  • 78 views
  • May 4, 2023
32:03

Indy Hematology Review

Emerging and Current Treatment of MM: What Should We Know and What Should We Do

FEATURING Kenneth Anderson
  • 637 views
  • April 18, 2023
  • 4
54:12

Dana-Farber Cancer Institute

Symptom Management in Multiple Myeloma

FEATURING Shonali Midha
  • 132 views
  • March 9, 2023
44:49

Dana-Farber Cancer Institute

Recent Updates in Multiple Myeloma

FEATURING Kenneth Anderson
  • 733 views
  • March 9, 2023
  • 9
27:10

Yale Cancer Center

Highlights in R/R Myeloma and AL Amyloidosis From ASH 2022

FEATURING Sabrina Browning
  • 35 views
  • March 8, 2023
19:18

Total Health

Updates to Management of Patients With Multiple Myeloma

FEATURING Shaji Kumar
  • 234 views
  • October 20, 2022
41:46

Yale Cancer Center

Early Detection and Interception in Myeloma: The PROMISE Study

FEATURING Irene Ghobrial
  • 125 views
  • March 22, 2023
  • 1
17:32

Current Challenges in Hematology

Patient Journey for a Transplant-Ineligible Patient With MM From 1L to Subsequent Lines

FEATURING Roberto Mina
  • 25 views
  • February 7, 2023
15:32

ASH 2022 Conference Coverage

Novel Approaches to Myeloma Burden Assessment

FEATURING Taxiarchis Kourelis
  • 254 views
  • December 19, 2022
  • 2
06:16

ASH 2022 Conference Coverage

U.S. Myeloma CAR-T Consortium Real World Experience: Factors Associated With Refractoriness or Early Progression After Ide-Cel in Pts With R/R MM

FEATURING Hamza Hashmi
  • 209 views
  • December 22, 2022
  • 1
14:16

ASH 2022 Conference Coverage

Assessing Disease Risk in Multiple Myeloma: High or Low?

FEATURING Timothy Schmidt
  • 132 views
  • December 28, 2022
  • 2
12:43

Oliver Van Oekelen

Outcomes of MM Pts Progressing After BCMA-Targeted CAR T-Cell Therapy

  • 70 views
  • January 4, 2023
  • 1